Efalizumab binding to the LFA-1 αL i domain blocks ICAM-1 binding via steric hindrance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 11, 2009, Pages 4349-4354

  Li, Sheng ^a   Wang, Hao ^b   Peng, Baozhen ^a   Zhang, Meilan ^a   Zhang, Daipong ^b   Hou, Sheng ^b   Guo, Yajun ^b   Ding, Jianping ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ALPHA CHAIN; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; INHIBITION KINETICS; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STEREOSPECIFICITY;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BINDING SITES; CELL MIGRATION INHIBITION; EPITOPES; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; PROTEIN BINDING;

EID: 63149149418     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0810844106     Document Type: Article

References (59)

1. Kishimoto TK, et al. (1989) The leukocyte integrins. Adv Immunol 46:149-182.
2. Ruoslahti E (1991) Integrins. J Clin Invest 87:1-5.
3. Shimaoka M, Takagi J, Springer TA (2002) Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct 31:485-516.
4. Stefanidakis M, Koivunen E (2006) Cell-surface association between matrix metal-loproteinases and integrins: Role of the complexes in leukocyte migration and cancer progression. Blood108:1441-1450.
5. Luo BH, Carman CV, Springer TA (2007) Structural basis of integrin regulation and signaling. Annu Rev Immunol 25:619-647.
6. Sanchez-Madrid F, Nagy JA, Robbins E, Simon P, Springer TA (1983) A human leukocyte differentiation antigen family with distinct α-subunits and a common β-subunit: The lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/
7. Mac-1), and the p150, 95 molecule. J Exp Med 158:1785-1803.
8. Gahmberg CG, Tolvanen M, Kotovuori P (1997) Leukocyte adhesion-structure and function of human leukocyte β2-integrins and their cellular ligands. Eur J Biochem 245:215-232.
9. Giblin PA, Lemieux RM (2006) LFA-1 as a key regulator of immune function: Approaches toward the development of LFA-1-based therapeutics. Curr Pharm Des 12:2771-2795.
10. Arnaout MA (1990) Structure and function of the leukocyte adhesion molecules CD11/ CD18. Blood 75:1037-1050.
11. Makgoba MW, et al. (1988) ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature 331:86-88.
12. Shimaoka M, et al. (2003) Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112:99-111.
13. Yalamanchili P, Lu C, Oxvig C, Springer TA (2000) Folding and function of I domain-deleted Mac-1 and lymphocyte function-associated antigen-1. J Biol Chem 275:21877-21882.
14. Leitinger B, Hogg N (2000) Effects of I domain deletion on the function of the β2 integrin lymphocyte function-associated antigen-1. Mol Biol Cell 11:677-690.
15. Lee JO, Rieu P, Arnaout MA, Liddington RC (1995) Crystal structure of the Adomain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 80:631-638.
16. Qu A, Leahy DJ (1995) Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, αLβ2) integrin. Proc Natl Acad Sci USA 92:10277-10281.
17. Lee JO, Bankston LA, Arnaout MA, Liddington RC (1995) Two conformations of the integrin A-domain (I-domain): A pathway for activation? Structure 3:1333-1340.
18. Kallen J, et al. (1999) Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 292:1-9.
19. Qu A, Leahy DJ (1996) The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin. Structure 4:931-942.
20. Legge GB, et al. (2000) NMR solution structure of the inserted domain of human leukocyte function associated antigen-1. J Mol Biol 295:1251-1264.
21. Nishida N, et al. (2006) Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity 25:583-594.
22. Hartgring SA, Bijlsma JW, Lafeber FP, van Roon JA (2006) Interleukin-7 induced immuno-pathology in arthritis. Ann Rheum Dis 65(Suppl3):69-74.
23. Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263-271.
24. Ramsay AG, Marshall JF, Hart IR (2007) Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev 26:567-578.
25. Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lym-phangiogenesis. Nat Rev Cancer 8:604-617.
26. Schmidmaier R, Baumann P (2008) Anti-adhesion evolves to a promising therapeutic conceptin oncology. Curr Med Chem 15:978-990.
27. Nicolls MR, Gill RG (2006) LFA-1 (CD11a) as a therapeutic target. Am J Transplant 6:27-36.
28. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930-942.
29. Mehlis SL, Gordon KB (2003) The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 49:S44-50.
30. Champe M, McIntyre BW, Berman PW (1995) Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a. J Biol Chem 270:1388-1394.
31. Huang C, Springer TA (1995) A binding interface on the I domain of lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J Biol Chem 270:19008-19016.
32. Edwards CP, et al. (1995) Identification of amino acids in the CD11a I-domain important for binding of the leukocyte function-associated antigen-1 (LFA-1) to intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 270:12635-12640.
33. Binnerts ME, et al. (1996) Antibodies that selectively inhibit leukocyte function-associated antigen 1 binding to intercellular adhesion molecule-3 recognize a unique epitope within the CD11a I domain. J Biol Chem 271:9962-9968.
34. Lu C, Shimaoka M, Zang Q, Takagi J, Springer TA (2001) Locking in alternate conformations of the integrin αLβ2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci USA 98:2393-2398.
35. Lu C, Shimaoka M, Salas A, Springer TA (2004) The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1. J Immunol 173:3972-3978.
36. Werther WA, et al. (1996) Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157:4986-4995.
37. Gottlieb A, et al. (2000) Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 42:428-435.
38. Jullien D, et al. (2004) T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): Mechanisms of action. Dermatology 208:297-306.
39. Hildreth JE, August JT (1985) Thehuman lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1): Functional effects of subunit-specific monoclonal antibodies. J Immunol 134:3272-3280.
40. Dougherty GJ, Hogg N (1987) The role of monocyte lymphocyte function-associated antigen 1 (LFA-1) in accessory cell function. Eur J Immunol 17:943-947.
41. Stanfield RL, Zemla A, Wilson IA, Rupp B (2006) Antibody elbow angles are influenced by their lightchain class. J Mol Biol 357:1566-1574.
42. Davies DR, Cohen GH (1996) Interactions of protein antigens with antibodies. Proc Natl Acad Sci USA 93:7-12.
43. Lawrence MC, Colman PM (1993) Shape complementarity at protein/protein interfaces. J Mol Biol 234:946-950.
44. Shimaoka M, et al. (2006) AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc Natl Acad Sci USA 103:13991-13996.
45. Zhou T, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
46. Su HP, Golden JW, Gittis AG, Hooper JW, Garboczi DN (2007) Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology 368:331-341.
47. Davies DR, Padlan EA, Sheriff S (1990) Antibody-antigen complexes. Annu Rev Biochem 59:439-473.
48. Wilson IA, Stanfield RL (1994) Antibody-antigen interactions: New structures and new conformational changes. Curr Opin Struct Biol 4:857-867.
49. Mian IS, Bradwell AR, Olson AJ (1991) Structure, function and properties of antibody binding sites. J Mol Biol 217:133-151.
50. Casasnovas JM, Stehle T, Liu JH, Wang JH, Springer TA (1998) Adimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc Natl Acad Sci USA 95:4134-4139.
51. Bella J, Kolatkar PR, Marlor CW, Greve JM, Rossmann MG (1998) The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and asan LFA-1 integrin ligand. Proc Natl Acad Sci USA 95:4140-4145.
52. Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM (2008) Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13:365-373.
53. Karpusas M, et al. (2003) Crystal structure of the α1 β1 integrin I domain in complex with an antibody Fab fragment. J Mol Biol 327:1031-1041.
54. Pflugrath JW (1999) The finer things in X-ray diffraction data collection. Acta Crystallogr D55:1718-1725.
55. Otwinowski Z, Minor W, Carter CW, Jr (1997) Processing of X-ray diffraction data collected in oscillation mode. Meth Enzymol 276:307-326.
56. Brunger AT, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D 54:905-921.
57. McCoy AJ (2007) Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr D 63:32-41.
58. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D 60:2126-2132.
59. DeLano WL (2002) The PyMOL Molecular Graphics System. Available at http:// www.pymol.org. Accessed on Jan 8, 2008.